Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00.
A three-person arbitration panel overseen by Finra Dispute Resolution Services stunned the financial advice industry on ...
The largest arbitration award granted to retail clients is the third ruling against Stifel involving advisor Chuck Roberts.
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $18.00. The ...
Stock analysts at Stifel Nicolaus initiated coverage on shares of Cameco (NYSE:CCJ – Get Free Report) (TSE:CCO) in a research ...
For the second time in about two weeks, a FINRA arbitration panel has cited state statutes to slap a wealth management firm ...
Siegmann Brings Extensive Industry & Investment Experience to StifelST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today appointed Jonathan Siegmann as Managing ...
Xponential Fitness (XPOF – Research Report) received a Hold rating and a $12.00 price target from Stifel Nicolaus analyst Chris O`Cull ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results